In our study, metformin acted via APMK-dependent mechanism and we found that it increased partial and total AMPKα1 in AMN and cALD patient-derived cells consistent with a previous report [98] suggesting metformin can be a potential therapeutic agent for X-ALD. Here, PRKAA1 is linked to X-linked adrenoleukodystrophy.